Evidence for activation of mutated p53 by apigenin in human pancreatic cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 593-604

  King, Jonathan C ^a,b   Lu, Qing Yi ^a,c   Li, Gang ^a,d   Moro, Aune ^a   Takahashi, Hiroki ^a,b   Chen, Monica ^a,b   Go, Vay Liang W ^a   Reber, Howard A ^a,b   Eibl, Guido ^a,b   Hines, O Joe ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hirshberg Laboratories for Pancreatic Cancer Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; P53; Pancreatic cancer; PUMA

Indexed keywords

APIGENIN; CYTOCHROME C; DNA BINDING PROTEIN; PIFITHRIN ALPHA; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; PUMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COMPLEX FORMATION; CONTROLLED STUDY; DIET; DIET SUPPLEMENTATION; DNA BINDING; DRUG STABILITY; ENZYME INACTIVATION; ENZYME RELEASE; EVIDENCE BASED MEDICINE; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANIMALS; APIGENIN; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BENZOTHIAZOLES; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; HUMANS; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 84862779346     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.12.008     Document Type: Article

References (29)

1. Storniolo A.M., Enas N.H., Brown C.A., Voi M., Rothenberg M.L., Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999, 85:1261-1268.
2. Meyer H., Bolarinwa A., Wolfram G., Linseisen J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab. 2006, 50:167-172.
3. Ujiki M.B., Ding X.Z., Salabat M.R., Bentrem D.J., Golker L., Milam B., Talamonti M.S., Bell R.H., Iwamura Adrian T.E. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5:76-83.
4. Strouch M.J., Milam B.M., Melstrom L.G., McGill J.J., Salabat M.R., Ujiki M.B., Ding X.Z., Bentrem D.J. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas 2009, 38:409-415.
5. Seo H.S., Ju J.H., Jang K., Shin I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor α-negative breast cells. Nutr. Res. 2011, 31:139-146.
6. Zhong Y., Krisanapun C., Lee S.H., Nualsanit T., Sams C., Peungvicha P., Baek S.J. Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur. J. Cancer 2010, 46:3365-3374.
7. Cai X., Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16958-16963.
8. Janus F., Albrechtsen N., Dornreiter I., Wiesmüller L., Grosse F., Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell. Mol. Life Sci. 1999, 55:12-27.
9. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
10. Brosh R., Rotter B. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. 2009, 9:701-713.
11. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485.
12. Boyong L., Robinson D.H., Birt D.F. Evaluation of properties of apigenin and [G-3H] apigenin and analytic method development. J. Pharm. Sci. 1997, 86:721-725.
13. Gradolatto A., Basly J.P., Berges R., Teyssier C., Chagnon M.C., Siess M.H., Canivenc-Lavier M.C. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab. Dispos. 2005, 33:49-54.
14. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51:6304-6311.
15. Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn. J. Cancer Res. 1994, 85:1005-1014.
16. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., Goodman S.N., Sohn T.A., Hruban R.H., Yeo C.J., Kern S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57:1731-1734.
17. Ruggeri B., Zhang S.Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J. Human pancreatic adenocarcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992, 7:1503-1511.
18. Hussain S.P., Harris C.C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 1999, 428:23-32.
19. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 1999, 19:1202-1209.
20. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309:1732-1735.
21. Yu J., Wang Z., Kinzler K.W., Vogelstein B., Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1931-1936.
22. Callus B.A., Ekert P.G., Heraud J.E., Jabbour A.M., Kotevski A., Vince J.E., Silke J., Vaux D.L. Cytoplasmic p53 is not required for PUMA-induced apoptosis. Cell Death Differ. 2008, 15:213-215.
23. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11:577-590.
24. Ohno I., Eibl G., Odinokova I., Edderkaoui M., Damoiseaux R.D., Yazbec M., Abrol R., Goddard W.A., Yokosuka O., Pandol S.J., Gukovskaya A.S. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G63-G73.
25. Schuler M., Bossy-Wetzl E., Goldstein J.C., Fitzgerald P., Green D.R. p53 induces apoptosis by caspace activation through mitochondrial cytochrome c release. J. Biol. Chem. 2000, 275:7337-7342.
26. Agullo G., Gamet-Payrastre L., Manenti S., Viala C., Remesy C., Chap H., Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase c inhibition. Biochem. Pharmacol. 1997, 53:1649-1657.
27. Ruela-de-Sousa R.R., Fuhler G.M., Blom N., Ferrerra C.V., Aoyama H., Peppelenbosch M.P. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 2010, 1:1-12.
28. Lee S.H., Ryu J.K., Lee K.Y., Woo S.M., Park J.K., Yoo J.W., Kim Y.T., Yoon Y.B. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2005, 259:39-49.
29. Patel D., Shukla S., Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (a review). Int. J. Oncol. 2007, 30:233-245.